Bacterial toxoids and pertussis antigens (DTaP/Tdap)

Bacterial toxoids and pertussis antigens are the primary immunogenic components of vaccines designed to prevent diphtheria, tetanus, and pertussis (whooping cough). Diphtheria and tetanus toxoids are produced by the chemical inactivation of exotoxins from Corynebacterium diphtheriae and Clostridium tetani, respectively, rendering them non-toxic while maintaining their ability to elicit a protective immune response [1, 2]. The pertussis component in modern acellular vaccines consists of purified proteins from Bordetella pertussis, including pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae, which are involved in bacterial adhesion and pathogenesis [3]. Upon vaccination, these antigens are recognized by the host's immune system, stimulating the production of neutralizing antibodies and the development of long-lived memory B and T cells [4]. This immunological memory allows for a rapid and robust response upon subsequent exposure to the pathogens, effectively preventing disease. These antigens are critical for public health, having significantly reduced the global burden of these severe bacterial infections [5].

Other names

Diphtheria toxoidTetanus toxoidPertussis toxin (PT)Filamentous hemagglutinin (FHA)Pertactin (PRN)Fimbriae types 2 and 3 (FIM)Acellular pertussis antigens

These antigens act as immunogens that stimulate the host's immune system to produce neutralizing antibodies (antitoxins) and prime T-cell responses. Diphtheria and tetanus toxoids induce antibodies that neutralize the respective bacterial exotoxins, while pertussis antigens elicit antibodies that prevent bacterial adhesion and neutralize the toxin's systemic effects.